WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will report first-quarter 2026 financial results before market open on Thursday, May 7, and will host a conference call the same morning to discuss the results and provide a corporate update.
The call is scheduled for 8:30 a.m. Eastern Time. Investors can access the live webcast, including presentation slides, through the “Events & Presentations” section of the company’s website or by dialing 800-715-9871 domestically or +1 646-307-1963 internationally using conference ID 9970701.
A replay of the webcast will be available about two hours after the call and will remain archived for 90 days on the company’s website.
Palvella is a clinical-stage biotechnology company developing therapies for rare skin diseases and vascular malformations, including conditions for which no treatments have been approved by the U.S. Food and Drug Administration.
The company’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is being studied for microcystic lymphatic malformations, cutaneous venous malformations and angiokeratomas. A second candidate, QTORIN pitavastatin, is under development for disseminated superficial actinic porokeratosis.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.